{
    "id": 19367,
    "cites": 33,
    "cited_by": 7,
    "reference": [
        "Abramson, R. et al., 2004. Generic Drug Cost Containment in Medicaid: Lessons from Five State MAC Programs. Health Care Financing Review. 25(3): 25-34.",
        "Berndt, E. and Aitken, M., 2010. Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals the Quarter Century after the 1984 Waxman-Hatch Legislation. NBER Working Paper 16431.",
        "Berndt, E., McGuire T., and Newhouse, J. 2011. A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets. Forum for Health Economics & Policy, 14(2), Article 10.",
        "Berndt, E. and Newhouse, J., 2012. Pricing and Reimbursement in U.S. Pharmaceutical Markets.",
        "in Patricia Danzon and Sean Nicholson, eds., The Economics of the Biopharmaceutical Industry, New York: Oxford University Press, pg. 201-265 Brekke, K., Holmas, T., and Straume, O. 2011. Reference Pricing, Competition, and Pharmaceutical Expenditures: Theory and Evidence from a Natural Experiment. Journal of Public Economics, 95(7): 624-638.",
        "Centers for Medicare and Medicaid Services, 2013. Medicaid Covered Outpatient Prescription Drug Reimbursement Information by State, Quarter Ending March 2013. Available at http://www.medicaid.gov/Medicaid-CHIP-Program-Information/ByTopics /Benefits/Prescription-Drugs/Downloads/reimbursementchart-2Q2013.pdf Chabner, B., 2011. Drug Shortages\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009dA Critical Challenge for the Generic-Drug Market. New England Journal of Medicine, 365(23): 2147-2149.",
        "Ching, A., 2010. A Dynamic Oligopoly Structural Model for the Prescription Drug Market After Patent Expiration. International Economic Review, 51(4): 1175-1207.",
        "Congressional Budget Office, 2004. Medicaid\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Reimbursements to Pharmacies for Prescription Drugs. Available at http://www.cbo.gov/publication/16199.",
        "Dafny, L., 2005. How Do Hospitals Respond to Price Changes? American Economic Review, 95(5): 1525-1547.",
        "Danzon, P. et al., 2005. Alternative Strategies for Medicare Payment of Outpatient Prescription Drugs - Part B and Beyond. American Journal of Managed Care, 11(3): 173-180.",
        "Drug Topics Red Book, 1999. Medical Economics Co., Montvale, NJ.",
        "Duggan, M. and Scott-Morton, F., 2006. The Distortionary Effects of Government Procurement: Evidence from Medicaid Prescription Drug Purchasing. Quarterly Journal of Economics, 121(1): 1-30.",
        "Gruber, J. et al., 1999. Physician Fees and Procedure Intensity: The Case of Cesarean Delivery. Journal of Health Economics, 18(4): 473-490.",
        "Grabowski, H. and Vernon, J., 1992. Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act. Journal of Law and Economics, 35(2): 331350.",
        "Holmstrom, B. and Milgrom, P. 1991. Multitask Principal-Agent Analyses: Incentive Contracts, Asset Ownership, and Job Design. The Journal of Law, Economics, and Organization. 7:24-52.",
        "Jacobson, M. et al., 2010. How Medicare\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Payment Cuts for Cancer Chemotherapy Drugs Changed Patterns of Treatment. Health Affairs, 29(7): 1394-1402.",
        "Kaiser Family Foundation, 2002. Medicaid: Purchasing Prescription Drugs. Available at http://www.kff.org/medicaid/4025-index.cfm.",
        "Kolassa, E., 1994. Guidance for Clinicians in Discerning and Comparing the Price of Pharmaceutical Agents. Journal of Pain and Symptom Management, 9(4): 235-243.",
        "Kolassa, E., 1997. Elements of Pharmaceutical Pricing, Binghamton, NY: The Pharmaceutical Products Press.",
        "National Association of State Medicaid Directors, 2010. Post AWP Pharmacy Pricing and Reimbursement. Available at http://hsd.aphsa.org/home/doc/SummaryofWhitePaper.pdf.",
        "National Pharmaceutical Council, 2000. Pharmaceutical Benefits Under State Medical Assistance Programs. Available at http://www.npcnow.org/Public/Issues/i_rel_research/Medicaid_Pharmaceutical_Plan_Re sources.aspx.",
        "Office of the Attorney General, Medicaid Fraud Control Unit, State of New York, 2000. Letter to Medicaid Pharmacy Director of West Virginia. Available at: http://www.doj.state.wi.us/AWP/WestVirginia/TrialExhibits/WV_PLAINTIFFS_EXHIB IT_154.pdf Reiffen D. and Ward, M., 2005. Generic Drug Industry Dynamics. Review of Economics and Statistics, 87(1): 37-49.",
        "Shea, M., et al., 2008. Association between the Medicare Modernization Act of 2003 and Patient Wait Times and Travel Distance for Chemotherapy. JAMA, 300(2): 189-96.",
        "Texas Office of the Comptroller, 2003. Texas Health Care Claims Study. Available at: http://www.window.state.tx.us/specialrpt/hcc2003/ U.S. Department of Health and Human Services, Health Care Financing Administration, 2000. An Additional Source of Average Wholesale Price Data in Pricing Drugs and Biologicals Covered by the Medicare Program. Transmittal AB-00-86, HCFA-Pub. 60AB.",
        "U.S. Department of Health and Human Services, Office of Inspector General, 2001. Medicaid\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Use of Revised Average Wholesale Prices. Report No. OEI-03-01-00010.",
        "U.S. Department of Health and Human Services, Office of Inspector General, 2002. Medicaid Pharmacy -- Additional Analyses of the Actual Acquisition Cost of Prescription Drug Products. Report No. A-06-02-0041.",
        "U.S. Department of Health and Human Services, Office of Inspector General, 2004. Omission of Drugs from the Federal Upper Limit List in 2001. Report No. OEI-03-02-00670.",
        "U.S. Department of Health and Human Services, Office of Inspector General, 2004. Addition of Qualified Drugs to the Medicaid Federal Upper Limit List. Report No. OEI-03-04-00320.",
        "U.S. Department of Health and Human Services, Office of Inspector General, 2011. Replacing Average Wholesale Price: Medicaid Drug Payment Policy. Report No. OEI-03-11-00060.",
        "U.S. Department of Health and Human Services, Office of Inspector General, 2012. Analyzing Changes to Medicaid Federal Upper Limit Amounts. Report No. OEI-03-11-00650.",
        "U.S. Department of Justice (2010). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pharmaceutical Manufacturers to Pay $421.2 Million to Settle False Claims Act Cases.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Available at http://www.justice.gov/opa/pr/2010/December/10-civ-1398.html U.S. Department of Justice (2012). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093McKesson Corp. Pays U.S. More Than $190 Million to Resolve False Claims Act Allegations.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Available at http://www.justice.gov/opa/pr/2012/April/12-civ-539.html U.S. Government Accountability Office, 2001. Medicare Payments for Covered Outpatient Drugs Exceed Providers\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 Cost. Report No. GAO-01-1118.",
        "U.S. Government Accountability Office, 2002. Medicare Outpatient Drugs: Program Payments Should Better Reflect Market Prices. Dummit, L. - Testimony before the US Senate Subcommittee on Health, Committee on Finance, U.S. Senate.",
        "Yurukoglu, A., 2012. Medicare Reimbursements and Shortages of Sterile Injectable Pharmaceuticals. NBER Working Paper 17987."
    ]
}